Further experiments verified that treatment with TM effectively inhibited the N-glycosylation modification of FOXD1 and led to a decrease in the molecular weight of the FOXD1 protein band in NPC cells transfected with either the wild-type plasmid (WT) or the mutant plasmid at Asn457. The gene discussed is FOXD1; the disease is nasopharyngeal carcinoma.